Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
38 Results for "
CLL1
" in MedChemExpress (MCE) Product Catalog:
Products (38)
38 Results for "CLL1" in MCE Product Catalog:
1
1 Cited Publications
Synonyms: Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride
Cat. No.: HY-P9961
CAS No.: 679818-59-8
Synonyms: GSK1841157; OMB-157
Synonyms: TAK-659 monohydrochloride; CB-659 monohydrochloride
TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .
Domaines de recherche:
PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of BRD4 that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC50 values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)) [1].\n
Cat. No.: HY-P991224
Target:
Domaines de recherche:
Cat. No.: HY-164995
CAS No.: 2417370-68-2
Domaines de recherche:
L1BC8 (Compound 13a) is a drug-linker conjugate for ADC. L1BC8 is obtained by conjugating a BRD4 PROTAC degrader with a peptidomimetic protease-cleavable linker for the preparation of ADC, which can be conjugated to STEAP1 antibodies and CLL1 antibodies, respectively. L1BC8 can be used in research related to prostate cancer and acute myeloid leukemia [1].
Cat. No.: HY-171499
CAS No.: 872847-66-0
Synonyms: EL625
Cenersen (EL625) is an oligonucleotide targeting TP53. Cenersen can eliminate the activity of TP53 gain-of-function mutants and increase the sensitivity of lymphoma cells to cytotoxic chemotherapy in vitro. Cenersen can be used for the study of chronic lymphocytic leukemia (CLL) .
Cat. No.: HY-160966
CAS No.: 2988804-46-0
Synonyms: PROTAC BTK Degrader-10
Domaines de recherche:
Omtebrutideg (PROTAC BTK Degrader-10) (Example 1P) is a PROTAC degrader for BTK. Omtebrutideg can be used for research of chronic lymphocytic leukemia (CLL) .
Cat. No.: HY-100867
CAS No.: 1312691-33-0
Synonyms: TAK-659; CB-659
TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .
Cat. No.: HY-177058
Target:
Domaines de recherche:
DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a TLR9 agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL) .
Cat. No.: HY-P12362
CAS No.: 2763825-83-6
Domaines de recherche:
CLL1-L1 is a peptide ligand targeting CLL1, which binds to CLL1 on leukemia stem cells and enables selective targeting of CLL1-expressing cells. CLL1-L1 can be covalently coated onto telodendrimer nanomicelles to mediate drug delivery to leukemia stem cells. CLL1-L1 is useful for research related to leukemia drug delivery [1] .
Cat. No.: HY-163607
CAS No.: 3033533-25-1
SpiD3, a spirocyclic dimer, is an anticancer agent. SpiD3 markedly inhibits malignant B-cell proliferation and suppressed NF-κB activation independent of TME-associated stimuli. SpiD3 induces apoptosis and inhibits protein synthesis in chronic lymphocytic leukemia cells. SpiD3 can be used for study of chronic lymphocytic leukemia (CLL) .
Cat. No.: HY-114461
CAS No.: 147025-57-8
Target:
Domaines de recherche:
FD-895 is a spliceosome modulator derived from a polyketide natural product, targeting the SF3b subunit of the spliceosome. FD-895 possesses core biological activities for regulating RNA splicing (intron retention, alternative splicing) and inducing apoptosis of cancer cells. FD-895 can be used for the research of cancer, such as chronic lymphocytic leukemia (CLL) .
Cat. No.: HY-17600R
CAS No.: 1420477-60-6
Synonyms: ACP-196 (Standard)
Target:
Domaines de recherche:
Acalabrutinib (Standard) is the analytical standard of Acalabrutinib. This product is intended for research and analytical applications. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL) . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-108052R
CAS No.: 6906-38-3
Synonyms: Delphinidin 3-O-glucoside chloride (Standard); Delphinidin 3-O-β-glucoside chloride (Standard)
Category:
Anthocyans Plant Flavonoids Malvaceae Extract Hibiscus sabdariffa Linn. Extract Microorganism
Target:
Cat. No.: HY-129937
CAS No.: 2738533-33-8
Domaines de recherche:
(S)-GNE-987 is an isomer of GNE-987 (HY-129937A), which loses VHL binding capacity and BRD4 protein degradation activity, but retains BRD4 inhibitory activity. (S)-GNE-987 is a BRD4/BET inhibitor that potently binds to the BD1 and BD2 bromodomains of BRD4, with a BRD4 BD1 IC50 of 4.0 nM and a BRD4 BD2 IC50 of 3.9 nM. (S)-GNE-987 inhibits MYC expression and exhibits inhibitory activity against acute myeloid leukemia cells, whereas its CLL1‑6 antibody-drug conjugate shows almost no in vivo antitumor efficacy in the HL‑60 xenograft tumor model. (S)-GNE-987 can be used in related research on acute myeloid leukemia [1].
Cat. No.: HY-P78623
Pureté: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CLEC12A; CLL1; C-Type Lectin Domain Family 12 Member A; C-Type Lectin Domain Family 12, Member A; DCAL-2; C-Type Lectin-Like Molecule-1; CLL-1; C-Type Lectin-Like Molecule 1; MICL; C-Type Lectin Protein CLL-1; Myeloid Inhibitory C-Type Lectin-Like Recepto
Species:
Rat
Source:
HEK293
Cat. No.: HY-P76267
Pureté: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CLEC12A; CLL1; C-Type Lectin Domain Family 12 Member A; C-Type Lectin Domain Family 12, Member A; DCAL-2; C-Type Lectin-Like Molecule-1; CLL-1; C-Type Lectin-Like Molecule 1; MICL; C-Type Lectin Protein CLL-1; Myeloid Inhibitory C-Type Lectin-Like Recepto
Species:
Human
Source:
HEK293
Cat. No.: HY-P77903
Pureté: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: CLEC12A; CLL1; C-Type Lectin Domain Family 12 Member A; C-Type Lectin Domain Family 12, Member A; DCAL-2; C-Type Lectin-Like Molecule-1; CLL-1; C-Type Lectin-Like Molecule 1; MICL; C-Type Lectin Protein CLL-1; Myeloid Inhibitory C-Type Lectin-Like Recepto
Species:
Cynomolgus
Source:
HEK293
Cat. No.: HY-P77631
Pureté: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: CLEC12A; CLL1; C-Type Lectin Domain Family 12 Member A; C-Type Lectin Domain Family 12, Member A; DCAL-2; C-Type Lectin-Like Molecule-1; CLL-1; C-Type Lectin-Like Molecule 1; MICL; C-Type Lectin Protein CLL-1; Myeloid Inhibitory C-Type Lectin-Like Recepto
Species:
Human
Source:
HEK293
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
